Adnan A Elfarra

US Patent:

20040023994, Feb 5, 2004

Filed:

Jun 4, 2003

Appl. No.:

10/454443

Inventors:

Adnan Elfarra - Madison WI, US
Sjofn Gunnarsdottir - Madison WI, US

International Classification:

A61K031/522

US Classification:

514/263300, 514/263380

Abstract:

The present invention relates to a method for treating a tumor in a tissue of a human or non-human animal, the tumor having an elevated level of glutathione relative to the tissue, the method comprising the steps of administering to the animal a prodrug comprising a thiopurine having a sulfur heteroatom conjugated to an alpha-, beta-unsaturated carbonyl moiety, in combination with a pharmaceutically acceptable carrier, the moiety comprising a double bond having an alpha end and a beta end, the beta end being accessible to glutathione in an addition-elimination reaction, the prodrug lacking an ionizable carboxylic acid group; and observing a reduction in growth of the tumor.

US Patent:

20050119284, Jun 2, 2005

Filed:

Sep 30, 2004

Appl. No.:

10/711681

Inventors:

Robert Striker - Madison WI, US
Adnan Elfarra - Madison WI, US
Sjofn Gunnarsdottir - Madison WI, US
Spencer Hoover - Madison WI, US

International Classification:

A61K031/522

US Classification:

514263300

Abstract:

The present invention provides therapeutic methods of inhibiting RNA viruses based on the newly-discovered anti-viral activity of cis or trans-6-(2-acetylvinylthio)purine (cis-AVTP) or (trans-AVTP). RNA viruses inhibited by the methods include flaviviruses, namely hepatitis C virus (HCV) and bovine diarrhea virus (BVDV).

US Patent:

50100920, Apr 23, 1991

Filed:

Dec 22, 1989

Appl. No.:

7/454884

Inventors:

Adnan A. Elfarra - Madison WI

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

A01N 4364
A01N 4382
A01N 4378
A01N 4350

US Classification:

514359

Abstract:

Drug treatment therapies and kits for use therewith are disclosed. They involve the use of methimazole and/or its pro-drug carbimazole to reduce nephrotoxic effects of chemical exposure. In one embodiment, a patient receives cisplatin and then is treated with methimazole. The time delay in providing methimazole prevents the methimazole from being substantially expelled by the kidney prior to cisplatin reaching the kidney.

US Patent:

50874411, Feb 11, 1992

Filed:

Feb 8, 1991

Appl. No.:

7/652964

Inventors:

Adnan A. Elfarra - Madison WI

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

A61K 4900
A01N 4350
A01N 4352

US Classification:

424 10

Abstract:

Drug treatment therapies and kits for use therewith are disclosed. They involve the use of methimazole and/or its pro-drug carbimazole to reduce nephrotoxic effects of chemical exposure. In one embodiment, a patient receives cisplatin and then is treated with methimazole. The time delay in providing methimazole prevents the methimazole from being substantially expelled by the kidney prior to cisplatin reaching the kidney.

US Patent:

51207400, Jun 9, 1992

Filed:

Jun 25, 1990

Appl. No.:

7/542664

Inventors:

Adnan A. Elfarra - Madison WI

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

A61K 31495
C07D47324
C07D47338

US Classification:

514262

Abstract:

Prodrugs for the treatment of kidney tumors are disclosed. The prodrugs are conjugates that can require the cooperation of multiple enzymes in the kidney to release 6-mercaptopurine or 6-thioguanin, or can selectively release 6-thioguanine. Methods for use of these prodrugs are also disclosed.